Home
Stampa
Poster Area

Antiretroviral Therapy

Chairs: R. Maserati, P. Nasta

OP 1

Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
M. Santoro, Roma

OP 2

Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort
A. Lanari, Siena

OP 3

Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database
F. Lombardi, Roma

OP 4

Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients
F. Lagi, Firenze

OP 5

Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison
A. Borghetti, Roma

OP 6

Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders
S. Milella, Bari

OP 7

Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis
R. Pincino, Genova

OP 8

Increase in body weight after a year of INI-exposure in a multicenter italian cohort
A. Ciccullo, Roma

OP 9

Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018
D.F. Bavaro, Bari

OP 10

Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to D. Cotugno Hospital, Naples, period 2017-2019
F.M. Fusco, Napoli

OP 11

Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort
A. Ciccullo, Roma

OP 12

Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis
A. Russo, Caserta


Basic Science and Immunology

Chairs: L. Butini, S. Piconi

OP 13

DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients
C. Agrati, Roma

OP 14

Sterol metabolism modulates susceptibility to HIV-1 Infection
I. Saulle, Milano

OP 15

Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection
A. Cossarizza, Modena

OP 16

HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition
G. Nannini, Firenze

OP 17

Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients
G. De Girolamo, Roma

OP 18

p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection
V. Bordoni, Roma

OP 19

Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults
L. Taramasso, Milano

OP 20

Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects
S. Cannizzo, Milano

OP 21

Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study
L. Taramasso, Milano

OP 22

An atypical case of HIV-1 elite controller: 15 years of follow up
C. Fimiani, Roma


Clinical HIV

Chairs: M. Borderi, A. Ruggieri

OP 23

Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign
G. Zuglian, Brescia

OP 24

Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome
L. Calza, Bologna

OP 25

Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPO Cohort
E. Focà, Brescia

OP 26

Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis
M. Poliseno, Bari

OP 27

Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
L. Calza, Bologna

OP 28

Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals
G. Lapadula, Monza

OP 29

Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression
C. Muccini, Milano

OP 30

A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort
D. Farinacci, Roma

OP 31

Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice
D. Armenia, Roma

OP 32

Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)
N. Gregori, Brescia

OP 33

Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
M. Masini, Siena

OP 34

Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)
M. Camici, Roma


Clinical HIV II

Chairs: R. Bellagamba, V. Giacomet

OP 35

Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series
C. Oltolini, Milano

OP 36

Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV
L. Caiazzo, Chieti

OP 37

A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study
A. Emiliozzi, Siena

OP 38

HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy
E. Asperges, Pavia

OP 39

Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)
V. Mazzotta, Roma

OP 40

Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load
A. Primavera, Bologna

OP 41

Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience
D. Canetti, Milano

OP 42

Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
C. Muccini, Milano

OP 43

Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?
F.M. Fusco, Napoli

OP 44

Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics
M. Ferrara, Torino


Comorbidities

Chairs: F. Carli, P. Maggi, I. Maida

OP 45

Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial
G. Lapadula, Monza

OP 46

Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH
G. Dolci, Modena

OP 47

Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV
M. Trunfio, Torino

OP 48

Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients
A.C. Brita, Roma

OP 49

Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?
A. Vergori, Roma

OP 50

Gender differences in neurocognitive functions in PLWK
V. Delle Donne, Roma

OP 51

Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
D. Morini, Modena

OP 52

NAFLD phenotype and prevalence across the menopause spectrum in women with HIV
J. Milic, Modena

OP 53

Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia
E. Schiaroli, Perugia

OP 54

Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis
V. Gentile, Caserta


Hepatitis and Coinfections

Chairs: O. Armignacco, M. Massari, C. Sagnelli

OP 55

Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR
M. Antonello, Milano

OP 56

Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men
R. Rossotti, Milano

OP 57

HCV infection in PWUD: a microelimination intervention in Rome
C. Taibi, Roma

OP 58

Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study
L. Onorato, Napoli

OP 59

Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort
A. Boschini, Coriano RN

OP 60

Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population
T. Mulas, Roma

OP 61

Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients
V. Castelli, Milano

OP 62

Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
M. Starace, Napoli

OP 63

Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort
M.G. Quaranta, Roma

OP 64

The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
M. Alkhatib, Roma

OP 65

HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics
L. Onorato, Napoli

OP 66

HEV infection as an emergent public health issue: is it a concern for Italian blood donors?
L. Colagrossi, Milano


Social Science and Prevention

Chairs: S. Babudieri, B.M. Celesia, M.G. Di Benedetto

OP 67

HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies
M. Maffeo, Milano

OP 68

Testing MSM in cruising venues
D. Zagato, Milano

OP 69

Behavioral aspects of MSM tested in community-based settings in 5 cities
M. Breveglieri, Bologna

OP 70

Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic
C. Rogati, Modena

OP 71

Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy
R. Rossotti, Milano

OP 72

NEETagers for the prevention of HIV and AIDS
V. Corallino, Perugia

OP 73

Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study
G.C. Orofino, Torino

OP 74

Women and HIV in prison setting: a data up date from the Italian ROSE network
E. Rastrelli, Viterbo

OP 75

First-year experience of an HIV clinic-based stop-smoking service
V. Spagnuolo, Milano

OP 76

Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life
R. Rossotti, Milano


Virology and Pharmacology

Chairs: R. Cavallo, S. Parisi

OP 77

The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase
M. Lai, Pisa

OP 78

Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15
L. Manganaro, Milano

OP 79

Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple
C. Fenizia, Milano

OP 80

Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays
I. Vicenti, Siena

OP 81

Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients
A. Amendola, Roma

OP 82

Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data
C. Alteri, Milano

OP 83

HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?
D. Armenia, Roma

OP 84

Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS
D. Vita, Milano

OP 85

Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line
F. Falasca, Roma

OP 86

A real-life experience of vaccination strategies for HBV prevention in HIV patients
D. Tomasoni, Milano

OP 87

A successful experience of an immunization program in HIV-positive adults
G. Chieffo, Busto Arsizio VA

OP 88

Plasma exchange and dolutegravir exposure. A case report
M. Mussa, Alessandria


Poster: Bacterial and fungal infections in immunocompromised host

P 1

A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center

P 2

Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report

P 3

Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center

P 4

Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery

P 5

A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment


Poster: Basics in viral hepatitis

P 6

Comparison of immunoassays for quantitative serum HBsAg

P 7

Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay


Poster: Cancers in HIV

P 8

The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people

P 9

Non-AIDS-defining cancers in a cohort of HIV positive patients

P 10

Case report on oncopathology in HIV-infected patients

P 11

Primitive NHL of bone in an HIV patient: case-report and review of literature

P 12

Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study

P 14

Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients

P 15

HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV

P 16

Epidemiological analysis from a newly established anal HPV screening ambulatory


Poster: Gender issues

P 17

Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda

P 18

Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study

P 19

Transgender people and HIV

P 20

HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study

P 21

HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART


Poster: HCV elimination

P 22

Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication

P 23

A fast track city micro-project to eradicate HCV infection in PLWHIV

P 24

A pilot intervention for HCV elimination among MSM in Rome: preliminary results

P 25

HCV eradication in people living with HIV in Sassari: the final countdown?

P 26

Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation

P 27

Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer

P 28

How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users

P 29

Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD)

P 30

Short course therapy for chronic hepatitis C infection

P 31

DAA failure in HCV genotype 3: virological features and efficacy of re-treatment

P 32

Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome

P 33

Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis

P 34

Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk

P 35

Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases

P 36

Feasibility and impact of HCV treatment in a HRS in Milan

P 37

An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan

P 38

Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment

P 39

EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy

P 40

Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection

P 41

HCV treatment in PWID: a linkage to care model in Cagliari


Poster: Hepatitis epidemiology

P 42

Hepatitis A: has the outbreak ended?

P 43

Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort

P 44

HEV in Southern Italy. Still a chimera?

P 45

Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals


Poster: HIV and COVID

P 46

Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy

P 47

A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection

P 48

SARS-CoV-2 infection in a highly-experienced person living with HIV

P 49

SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report

P 50

COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome

P 51

Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy

P 52

Management of emergency COVID-19 in prison, Monza experience

P 53

Psychological impact and awareness of COVID-19 in young people with HIV

P 54

Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor?

P 55

Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients


Poster: HIV and nervous system

P 56

Study of the types of the nervous system based on temperaments of HIV-infected patients

P 57

Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression

P 58

Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV

P 59

Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients

P 60

Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab

P 61

In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition

P 62

Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study

P 63

Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV

P 64

Cryptococcal meningitis in a young woman HIV late presenter: a case report


Poster: HIV cure

P 65

A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naive patients: background and preliminary data of a pilot project of the GLAD group

P 66

Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir+Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks

P 67

Complementary-alternative medicines and self prescribed drugs use in women living with HIV


Poster: HIV epidemiology and retention in care

P 68

Availability of rapid HIV self-test in Italian pharmacies: a survey

P 69

REducing LAte Presenters Patients rate in Milan area (RELAPP Study): preliminary results

P 70

May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience

P 71

High rates of lost-to-follow-up among naive HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19

P 72

Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital

P 73

Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population?

P 74

The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients

P 75

Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019

P 76

"EXTERNA": QoL Perception in PLWHIV during ID checkup

P 77

HIV screening in migrant population living in "ghetti" in Apulia

P 78

Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System

P 79

Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection

P 80

HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey

P 81

Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova

P 82

Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival

P 83

New diagnoses of HIV infection: what has changed in 10 years


Poster: HIV immunology and immune-based therapies

P 84

Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients

P 85

Influence of HLA haplotype on immunological recovery in HIV-infected patients


Poster: HIV pathogenesis

P 86

Oxidative Stress and gut microbiota composition in primary HIV infection


Poster: HIV prevention (PrEP and PEP)

P 87

PrEP awareness and attitudes in a survey among Italianclinicians

P 88

PrEP: the stories about who used the therapy

P 89

Young People Inform Young People - Speak to the students with the Peer Section of the School Project

P 90

Problems and difficulties in the management of a PrEP clinic

P 91

Post-exposure prophylaxis in real life

P 92

Determinants of drug start, schedule change and discontinuation in PrEP users

P 93

No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex

P 94

PreP: psychological and emotional aspects

P 95

PrEP use amongst MSM in Italy: data from the EMIS 2017 survey

P 96

Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence

P 97

In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide


Poster: HIV virology

P 98

Undetectable versus low level HIV viremia on patients taking antiretroviral therapy

P 99

Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients

P 100

HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection

P 101

New potential anti-HIV agents: the antimicrobial peptide Temporin L

P 102

Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients

P 103

HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test

P 104

Influence of HIV-1 V2 domain characteristics on immunological recovery under ART

P 105

Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates

P 106

Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry

P 107

In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations

P 108

Does HLA-C binding stability affect HIV-1 infection?

P 109

Genotipic Resistance test in rapid ART era


Poster: HIV-associated tuberculosis

P 110

Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV


Poster: Issues on antiretroviral therapy

P 111

Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients

P 112

Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis

P 113

HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy

P 114

Side effects detected in HIV-positive patients depending on the ART regimen

P 115

Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection

P 116

A rare case of acute tubular necrosis tenofovir alafenamide-related

P 117

New cases of diabetes dolutegravir-associated in HIV patients: a case series

P 118

Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART

P 119

Viral outcome on tailored treatment strategyusing cost saving antiretroviral (ARV)

P 120

The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study

P 121

Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors-based regimens

P 122

Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice

P 123

Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life

P 124

Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV

P 125

An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)

P 126

Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype

P 127

Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients

P 128

Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center

P 129

Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients

P 130

Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy

P 131

Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir

P 132

Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection

P 133

Evaluation of lipid profile in HIV naive patients, treated by TAF-based regimens


Poster: Management and treatment of viral hepatitis

P 134

Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure

P 135

Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study

P 136

DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment

P 137

Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy

P 138

Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona

P 139

Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bictegravir/emtricitabine/tenofovir alafenamide

P 140

Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy

P 141

Current management of hepatitis B in sclerosis patients treated with disease-modify therapies


Poster: Management of HIV infection

P 142

Effect of 12-week physical activity program on sarcopenia measures in people living with HIV

P 143

Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study

P 144

HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays

P 145

Intestinal Alkaline Phosphatase levels in HIV infected patients

P 146

Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer

P 147

Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report


Poster: Non infectious comorbidities in HIV

P 148

3TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density

P 149

HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities

P 150

Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy

P 151

Cardiovascular disease risk markers in a small cohort of HIV-infetcted patietns switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir

P 152

Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort

P 153

Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART

P 154

Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study)

P 155

A structured smoking cessation intervention in a single centre in patients living with HIV

P 156

Physical activity levels in HIV+ cohort of Pavia

P 157

Machine learning vs Knowledge based approach in health outcomes' prediction in HIV

P 158

Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPPO cohort)

P 159

Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patients

P 160

Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study

P 161

Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment

P 162

Archi-Prevaleat project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV


Poster: Pediatric, adolescent, maternal, fetal aspects

P 163

Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy


Poster: Pharmacology, pharmacogenomics and drug interactions

P 164

Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd]azulene-2-carboxylic acid derivatives

P 165

Antiviral activity of of 6-(4-methylbenzyl)-3-arylamino-4н-[1,2,4]triazin-5-оne derivatives against yellow fever

P 166

Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient


Poster: Social and behavioural science, marginalized groups, community aspects and community surveys

P 167

A survey as a chance of education on U=U in Italian general population

P 168

Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE

P 169

HIV prescriptivetrend 2018 vs 2019 in a teaching hospital in Rome

P 170

HAARTisticamente An unusual fashion show

P 171

"La prevenzione va in tournèe" a social experiment and on the field experience on HIV/STIs and social integration

P 172

Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience

P 173

HIV rapid testing outside healthcare facilities: diagnostic and educational tool

P 174

Changes in causes of death of people living with HIV in a large teaching hospital in Rome

P 175

The PLWH perception of long acting injectable therapy

P 176

Cohort observational study and HIV brochure in a teaching hospital in Rome

P 177

HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations

P 178

Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project*

P 179

School and HIV. Cognitive and Emotional aspects for effective communication

P 180

Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team

P 181

"TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U"

P 182

Test, condom and chems: how the habits of people in Milan change. A test experience in a premise

P 183

Coming out surrealista

P 184

App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus

P 185

PrEP between desire and needing: 2020 update

P 186

Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point

P 187

Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV

P 188

The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV sinergy. Preliminary data analysis

P 189

HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey

P 190

Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus

P 191

Linkage to care in HIV: the point of view of people with recent diagnosis

P 192

AIDS and other sexually transmitted diseases: what do young people know? - a Cross Sectional Study

P 193

Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic

P 194

SRHR Sensitization and Education activities from Medical Students

P 195

"Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna

P 196

WE TEST - National community-based HIV prevention program


Poster: Vaccines

P 197

Anti-body response to pneumococcical vaccination in HIV patient after supplementation with probiotic

P 198

Adherence to the influenza vaccination campaign: experience of a large clinical center

P 199

HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study

P 200

Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience

P 201

Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey

P 202

Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix© in People Living with HIV

P 203

Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M.Annunziata Hospital, Florence


Poster: Cancers in HIV

P 13

Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster?


 
  • Poster Area
     

    Antiretroviral Therapy

    Chairs: R. Maserati, P. Nasta

    188Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
    M. Santoro,
    268Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort
    A. Lanari,
    281Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database
    F. Lombardi,
    117Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients
    F. Lagi,
    163Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison
    A. Borghetti,
    191Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders
    S. Milella,
    199Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis
    R. Pincino,
    5Increase in body weight after a year of INI-exposure in a multicenter italian cohort
    A. Ciccullo,
    226Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018
    D.F. Bavaro,
    92Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to D. Cotugno Hospital, Naples, period 2017-2019
    F.M. Fusco,
    217Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort
    A. Ciccullo,
    95Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis
    A. Russo,

    Basic Science and Immunology

    Chairs: L. Butini, S. Piconi

    309DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients
    C. Agrati,
    79Sterol metabolism modulates susceptibility to HIV-1 Infection
    I. Saulle,
    270Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection
    A. Cossarizza,
    277HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition
    G. Nannini,
    352Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients
    G. De Girolamo,
    263p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection
    V. Bordoni,
    19Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults
    L. Taramasso,
    151Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects
    S. Cannizzo,
    18Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study
    L. Taramasso,
    143An atypical case of HIV-1 elite controller: 15 years of follow up
    C. Fimiani,

    Clinical HIV

    Chairs: M. Borderi, A. Ruggieri

    276Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign
    G. Zuglian,
    16Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome
    L. Calza,
    275Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPO Cohort
    E. Focà,
    206Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis
    M. Poliseno,
    189Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
    L. Calza,
    28Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals
    G. Lapadula,
    250Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression
    C. Muccini,
    59A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort
    D. Farinacci,
    346Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice
    D. Armenia,
    295Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)
    N. Gregori,
    264Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
    M. Masini,
    259Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)
    M. Camici,

    Clinical HIV II

    Chairs: R. Bellagamba, V. Giacomet

    56Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series
    C. Oltolini,
    71Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV
    L. Caiazzo,
    177A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study
    A. Emiliozzi,
    216HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy
    E. Asperges,
    335Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)
    V. Mazzotta,
    68Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load
    A. Primavera,
    35Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience
    D. Canetti,
    252Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
    C. Muccini,
    119Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?
    F.M. Fusco,
    324Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics
    M. Ferrara,

    Comorbidities

    Chairs: F. Carli, P. Maggi, I. Maida

    51Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial
    G. Lapadula,
    120Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH
    G. Dolci,
    137Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV
    M. Trunfio,
    287Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients
    A.C. Brita,
    234Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?
    A. Vergori,
    175Gender differences in neurocognitive functions in PLWK
    V. Delle Donne,
    246Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
    D. Morini,
    230NAFLD phenotype and prevalence across the menopause spectrum in women with HIV
    J. Milic,
    84Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia
    E. Schiaroli,
    203Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis
    V. Gentile,

    Hepatitis and Coinfections

    Chairs: O. Armignacco, M. Massari, C. Sagnelli

    179Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR
    M. Antonello,
    153Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men
    R. Rossotti,
    97HCV infection in PWUD: a microelimination intervention in Rome
    C. Taibi,
    98Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study
    L. Onorato,
    322Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort
    A. Boschini,
    187Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population
    T. Mulas,
    342Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients
    V. Castelli,
    248Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
    M. Starace,
    47Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort
    M.G. Quaranta,
    312The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
    M. Alkhatib,
    134HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics
    L. Onorato,
    130HEV infection as an emergent public health issue: is it a concern for Italian blood donors?
    L. Colagrossi,

    Social Science and Prevention

    Chairs: S. Babudieri, B.M. Celesia, M.G. Di Benedetto

    104HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies
    M. Maffeo,
    106Testing MSM in cruising venues
    D. Zagato,
    370Behavioral aspects of MSM tested in community-based settings in 5 cities
    M. Breveglieri,
    29Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic
    C. Rogati,
    154Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy
    R. Rossotti,
    112NEETagers for the prevention of HIV and AIDS
    V. Corallino,
    90Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study
    G.C. Orofino,
    292Women and HIV in prison setting: a data up date from the Italian ROSE network
    E. Rastrelli,
    166First-year experience of an HIV clinic-based stop-smoking service
    V. Spagnuolo,
    148Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life
    R. Rossotti,

    Virology and Pharmacology

    Chairs: R. Cavallo, S. Parisi

    271The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase
    M. Lai,
    192Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15
    L. Manganaro,
    76Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple
    C. Fenizia,
    74Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays
    I. Vicenti,
    63Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients
    A. Amendola,
    208Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data
    C. Alteri,
    165HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?
    D. Armenia,
    96Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS
    D. Vita,
    291Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line
    F. Falasca,
    344A real-life experience of vaccination strategies for HBV prevention in HIV patients
    D. Tomasoni,
    235A successful experience of an immunization program in HIV-positive adults
    G. Chieffo,
    64Plasma exchange and dolutegravir exposure. A case report
    M. Mussa,

    Poster: Bacterial and fungal infections in immunocompromised host

    10A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center
    45Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report
    53Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center
    111Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery
    156A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment

    Poster: Basics in viral hepatitis

    288Comparison of immunoassays for quantitative serum HBsAg
    330Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay

    Poster: Cancers in HIV

    32The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people
    49Non-AIDS-defining cancers in a cohort of HIV positive patients
    116Case report on oncopathology in HIV-infected patients
    145Primitive NHL of bone in an HIV patient: case-report and review of literature
    253Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study
    320Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients
    351HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV
    358Epidemiological analysis from a newly established anal HPV screening ambulatory

    Poster: Gender issues

    139Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda
    204Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study
    225Transgender people and HIV
    232HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study
    365HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART

    Poster: HCV elimination

    6Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication
    37A fast track city micro-project to eradicate HCV infection in PLWHIV
    43A pilot intervention for HCV elimination among MSM in Rome: preliminary results
    58HCV eradication in people living with HIV in Sassari: the final countdown?
    69Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation
    83Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer
    100How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users
    124Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD)
    132Short course therapy for chronic hepatitis C infection
    133DAA failure in HCV genotype 3: virological features and efficacy of re-treatment
    186Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome
    212Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis
    244Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk
    285Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases
    313Feasibility and impact of HCV treatment in a HRS in Milan
    338An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan
    350Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment
    353EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy
    354Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection
    357HCV treatment in PWID: a linkage to care model in Cagliari

    Poster: Hepatitis epidemiology

    142Hepatitis A: has the outbreak ended?
    193Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort
    215HEV in Southern Italy. Still a chimera?
    243Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals

    Poster: HIV and COVID

    374Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy
    377A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection
    380SARS-CoV-2 infection in a highly-experienced person living with HIV
    381SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report
    386COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome
    388Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy
    389Management of emergency COVID-19 in prison, Monza experience
    391Psychological impact and awareness of COVID-19 in young people with HIV
    393Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor?
    395Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients

    Poster: HIV and nervous system

    140Study of the types of the nervous system based on temperaments of HIV-infected patients
    141Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression
    173Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV
    178Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients
    260Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab
    265In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition
    286Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study
    302Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV
    304Cryptococcal meningitis in a young woman HIV late presenter: a case report

    Poster: HIV cure

    183A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naive patients: background and preliminary data of a pilot project of the GLAD group
    329Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir+Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks
    336Complementary-alternative medicines and self prescribed drugs use in women living with HIV

    Poster: HIV epidemiology and retention in care

    44Availability of rapid HIV self-test in Italian pharmacies: a survey
    72REducing LAte Presenters Patients rate in Milan area (RELAPP Study): preliminary results
    81May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience
    87High rates of lost-to-follow-up among naive HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19
    149Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital
    157Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population?
    196The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients
    205Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019
    224"EXTERNA": QoL Perception in PLWHIV during ID checkup
    233HIV screening in migrant population living in "ghetti" in Apulia
    254Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System
    274Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection
    305HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey
    333Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova
    359Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival
    371New diagnoses of HIV infection: what has changed in 10 years

    Poster: HIV immunology and immune-based therapies

    91Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients
    240Influence of HLA haplotype on immunological recovery in HIV-infected patients

    Poster: HIV pathogenesis

    366Oxidative Stress and gut microbiota composition in primary HIV infection

    Poster: HIV prevention (PrEP and PEP)

    4PrEP awareness and attitudes in a survey among Italianclinicians
    14PrEP: the stories about who used the therapy
    21Young People Inform Young People - Speak to the students with the Peer Section of the School Project
    46Problems and difficulties in the management of a PrEP clinic
    52Post-exposure prophylaxis in real life
    146Determinants of drug start, schedule change and discontinuation in PrEP users
    147No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex
    159PreP: psychological and emotional aspects
    168PrEP use amongst MSM in Italy: data from the EMIS 2017 survey
    181Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence
    239In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide

    Poster: HIV virology

    158Undetectable versus low level HIV viremia on patients taking antiretroviral therapy
    169Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients
    174HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection
    184New potential anti-HIV agents: the antimicrobial peptide Temporin L
    194Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients
    273HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test
    315Influence of HIV-1 V2 domain characteristics on immunological recovery under ART
    318Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates
    319Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry
    325In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
    332Does HLA-C binding stability affect HIV-1 infection?
    373Genotipic Resistance test in rapid ART era

    Poster: HIV-associated tuberculosis

    210Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV

    Poster: Issues on antiretroviral therapy

    9Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients
    89Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis
    102HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy
    115Side effects detected in HIV-positive patients depending on the ART regimen
    118Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection
    129A rare case of acute tubular necrosis tenofovir alafenamide-related
    152New cases of diabetes dolutegravir-associated in HIV patients: a case series
    170Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART
    195Viral outcome on tailored treatment strategyusing cost saving antiretroviral (ARV)
    200The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study
    214Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors-based regimens
    220Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice
    222Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life
    245Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV
    258An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)
    284Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype
    289Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients
    301Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center
    314Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients
    323Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy
    337Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir
    339Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection
    361Evaluation of lipid profile in HIV naive patients, treated by TAF-based regimens

    Poster: Management and treatment of viral hepatitis

    23Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure
    48Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study
    73DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment
    78Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy
    94Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona
    218Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bictegravir/emtricitabine/tenofovir alafenamide
    363Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy
    364Current management of hepatitis B in sclerosis patients treated with disease-modify therapies

    Poster: Management of HIV infection

    11Effect of 12-week physical activity program on sarcopenia measures in people living with HIV
    85Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study
    135HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays
    227Intestinal Alkaline Phosphatase levels in HIV infected patients
    321Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer
    372Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report

    Poster: Non infectious comorbidities in HIV

    33TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density
    8HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities
    15Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy
    50Cardiovascular disease risk markers in a small cohort of HIV-infetcted patietns switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir
    65Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort
    101Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART
    138Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study)
    185A structured smoking cessation intervention in a single centre in patients living with HIV
    219Physical activity levels in HIV+ cohort of Pavia
    247Machine learning vs Knowledge based approach in health outcomes' prediction in HIV
    249Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPPO cohort)
    278Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patients
    290Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study
    347Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment
    367Archi-Prevaleat project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV

    Poster: Pediatric, adolescent, maternal, fetal aspects

    201Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy

    Poster: Pharmacology, pharmacogenomics and drug interactions

    123Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd]azulene-2-carboxylic acid derivatives
    136Antiviral activity of of 6-(4-methylbenzyl)-3-arylamino-4н-[1,2,4]triazin-5-оne derivatives against yellow fever
    360Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient

    Poster: Social and behavioural science, marginalized groups, community aspects and community surveys

    7A survey as a chance of education on U=U in Italian general population
    12Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE
    13HIV prescriptivetrend 2018 vs 2019 in a teaching hospital in Rome
    24HAARTisticamente An unusual fashion show
    33"La prevenzione va in tournèe" a social experiment and on the field experience on HIV/STIs and social integration
    34Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience
    41HIV rapid testing outside healthcare facilities: diagnostic and educational tool
    60Changes in causes of death of people living with HIV in a large teaching hospital in Rome
    70The PLWH perception of long acting injectable therapy
    82Cohort observational study and HIV brochure in a teaching hospital in Rome
    105HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations
    108Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project*
    110School and HIV. Cognitive and Emotional aspects for effective communication
    113Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team
    114"TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U"
    160Test, condom and chems: how the habits of people in Milan change. A test experience in a premise
    167Coming out surrealista
    207App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus
    209PrEP between desire and needing: 2020 update
    237Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point
    242Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV
    279The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV sinergy. Preliminary data analysis
    282HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey
    294Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus
    297Linkage to care in HIV: the point of view of people with recent diagnosis
    303AIDS and other sexually transmitted diseases: what do young people know? - a Cross Sectional Study
    343Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic
    348SRHR Sensitization and Education activities from Medical Students
    356"Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna
    369WE TEST - National community-based HIV prevention program

    Poster: Vaccines

    55Anti-body response to pneumococcical vaccination in HIV patient after supplementation with probiotic
    144Adherence to the influenza vaccination campaign: experience of a large clinical center
    155HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study
    161Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience
    180Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey
    190Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix© in People Living with HIV
    280Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M.Annunziata Hospital, Florence

    Poster: Cancers in HIV

    261Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster?
     
 
Plenary Room
Room 2
14.00 - 15.00
15.00 - 16.00

Pre-Conference advanced course

New frontiers in medical virology

Pre-Conference advanced course

New challenges in sexually transmitted infections: sexual health, prevention and more
 

Pre-Conference advanced course

Nurse management of patients with comorbidities
16.00 - 16.45

Satellite Symposium

Durable treatment success in HIV
16.45 - 18.30

Plenary Room

ICAR 2020 Opening Session

16.45 - 17.00: Introducing ICAR 2020 and Welcome Addresses

17.00 - 17.15: RaccontART HIV contest Awards

17.15 - 18.15: Keynote Lectures

18.15 - 18.30: Closing Remarks

 
  • Plenary Room
    14.00-15.00

    Pre-Conference advanced course

    New frontiers in medical virology

    Pre-Conference advanced course

    New frontiers in medical virology

    Infectious diseases are of public interest because of their impact on human, animal, and plant health. In this context, viruses play a central role in all aspects of medical research, ranging from molecular biology and immunology to evolution and epidemiology. The course will offer insight into the laboratory tools for the surveillance, diagnosis and monitoring of viral infections. It will also focus on novel aspects of viral pathogenesis and elaboration of therapeutic strategies.

    Chairs: I. Bon, B. Rossetti, C. Tincati

    14.00 - 14.10 Next-generation sequencing: a methodology changing the way to understand genome sequencing, evolution, ecology and discovery viruses
    N. Clementi
    14.10 - 14.20 Serological and molecular tools for detection of emerging viruses
    G. Rossini
    14.20 - 14.30 Role of HIV-1 protein variants in lymphoma pathogenesis
    F. Caccuri
    14.30 - 14.40 New frontiers of antiviral strategies
    O. Turriziani
    14.40 - 15.00 Discussion and conclusions
    15.00-16.00

    Pre-Conference advanced course

    New challenges in sexually transmitted infections: sexual health, prevention and more

    Pre-Conference advanced course

    New challenges in sexually transmitted infections: sexual health, prevention and more

    The consequences of sexually transmitted infections (STIs) on both individual and public health can be severe. The increasing incidence of STIs demands a call to action to ensure that populations at risk have access to comprehensive STIs prevention and care, especially in the context of expanded use of pre-exposure prophylaxis (PrEP) for HIV prevention. Integration of STIs services and PrEP is challenging but also provides a unique opportunity to optimize broader sexual and reproductive health services.

    Chairs: L. Badia, G. Cuomo, R. Rossotti

    15.00 - 15.10 Beyond PrEP: from a clinical management of STIs to a broader approach to sexual health
    M. Cordioli
    15.10 - 15.20 Test and Same Day Treatment in HIV: the role of screening and early ART initiation in the management of HIV
    A. Ciccullo
    15.20 - 15.30 Empowering people for their sexual health: how U=U changed the sexual lives of people living with HIV
    D. Calzavara
    15.30 - 15.40 Focus on vaccinations: are they an effective tool of sexual prevention?
    M. Digaetano
    15.40 - 16.00 Discussion and conclusions
    16.00-16.45

    Satellite Symposium

    Durable treatment success in HIV

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    Durable treatment success in HIV

    Thanks to the advent of increasingly effective antiretroviral drugs and the additional knowledge/experience gained, HIV infection is now a manageable chronic condition, in which the achievement of immune-viral control has become a reality for the majority of treated patients. Therefore, it becomes essential to "update" the clinicians' and patients' perspectives of the disease, targeting not only the mere control of the virus (both at the population and patient level) but also the global health of current PLWHIV. This latter aspect becomes even more crucial since patients still are vulnerable due to a residual disease driven by non-AIDS defined comorbidities. Reflecting on current challenges and available strategies to fill these gaps will be essential, also with the support of real-life data. These themes will be addressed in an interactive way, through a direct dialogue between physicians and patients.

    Chair: C. Mussini

    16.30 - 16.45 Global Health in HIV
    S. Vella
    16.45 - 17.15 Round Table "Strategies for durable treatment success"
    Participants: M. Andreoni, G. Di Perri, A. d'Arminio Monforte, G.M. Corbelli
    16.45-18.30

    ICAR 2020 Opening Session

    16.45 - 17.00: Introducing ICAR 2020
    Welcome Addresses

    17.00 - 17.15: RaccontART HIV contest Awards

    17.15 - 18.15: Keynote Lectures

    18.15 - 18.30: Closing Remarks

    ICAR 2020 Opening Session

    16.45 - 17.00 Introducing ICAR 2020
    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio
    17.00 - 17.15 RaccontART HIV contest Awards
    Chairs: A. Caraglia, M. Errico, A. Lazzarin
    17.15 - 18.15 Keynote Lectures
    Chairs: G.V. Calvino, A. Cossarizza, C.F. Perno, S. Vella
    17.15 - 17.35 Mauro Moroni Memorial Lecture "Immune control to reservoir: commencing countdown, control on"
    M. Paiardini
    17.35 - 17.55 Transgender, non-binary and HIV people: peculiarities of a key population between stigma and retaining in care
    O. Voza
    17.55 - 18.15 The public health response to new and future pandemics: lights and shadows from COVID-19
    G. Ippolito
    17.15 - 18.15 Closing Remarks
    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio
  • Room 2
    15.00-16.00

    Pre-Conference advanced course

    Nurse management of patients with comorbidities

    Pre-Conference advanced course

    Nurse management of patients with comorbidities

    Achieving an undetectable viral load is no longer the sole endpoint in treating HIV. Today's challenge is to guide patients towards a proactive management of HIV-associated comorbidities.  Therapies have improved notably: nowadays patients diagnosed with HIV and treated with the latest antiretrovirals have a life expectancy comparable to the general population. A recent study showed that in 2010 patients' mean age was 43.9 years, whereas in 2030 is expected to be 56.6 years, with patients aged over 50 increasing from 28% to 73%.  Nonetheless, there are more challenges to face: aging with HIV puts patients to an increased risk of developing HIV-related illnesses, such as osteoporosis, hepatic, cardiovascular and neurological disease.  It is therefore necessary for the nursing staff to be to able to lead patients to a successful management of their comorbidities through a learning process based on efficient means of communication aimed at patients' empowerment.

    Chairs: E. Bruni, M. Gatti, S. Patrucco

    15.00 - 15.10 Cardiovascular risk factors
    M. Belli
    15.10 - 15.20 Nurse management of frail and elderly HIV-positive patients
    M. Gatti
    15.20 - 15.30 Therapeutic Patient Education in subjects with neurocognitive disorders
    S. Ondedei
    15.30 - 15.40 Nurse management of cancer patients
    A. Meda
    15.40 - 15.50 The nurse's role in managing the risk of infection in HIV-positive patients
    E. Bruni
    15.50 - 16.00 Discussion
 
Plenary Room
Room 2
Room 3
14.30 - 14.50

Plenary Room

Keynote Lecture
15.00 - 16.00
16.00 - 17.00

Symposium

Virus persistence and host interactions

Satellite Symposium

Fighting multi drug resistance - the right moment, the right drugs

Expert Meeting

Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

Oral Communications

Social Science
 
17.00 - 17.20

Plenary Room

Keynote Lecture
17.30 - 18.30
18.30 - 19.30

Symposium

New metabolic challenges in comorbidities

Sponsored Symposium

Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine

Oral Communications

Antiretroviral Therapy

Oral Communications

HIV Prevention
Meet the Expert
  • Antiretroviral therapy
  • Transgender
19.30 - 20.30

Plenary Room

ICAR-CROI Awards 2020 for young Italian HIV investigators
 
  • Plenary Room
    14.30-14.50 Keynote Lectures

    Keynote Lecture

    Chairs: M. Farinella, C. Mussini

    14.30 - 14.50 Visions of ART
    A. Pozniak
    15.00-15.55

    Symposium

    Virus persistence and host interactions

    Symposium

    Virus persistence and host interactions

    Antiretroviral therapy (ART) has gained a great deal of success in recent years and succeeded in suppressing viral replication in people infected with HIV. Nevertheless, infected cells persist for decades on ART and HIV-RNA comes back if ART is stopped. Persistence has been attributed to viral replication in cellular/anatomical reservoirs and long-lived and/or proliferating latently infected cells. This symposium aims at shedding light on the fine mechanisms of persistence of retroviruses and their cross-talk with the host immune system.

    Chairs: G. Antonelli, P. Bagnarelli, S. Rusconi

    15.00 - 15.10 Restriction factors and the peculiar function of CIITA
    R. Accolla
    15.10 - 15.20 The persistence of memory: HIV reservoir and adaptive immunity
    F.R. Simonetti
    15.20 - 15.30 Gene editing: from the virus side
    M. Pistello
    15.30 - 15.40 Gene editing: from the cell side
    R. Bella
    15.40 - 15.55 Discussion on Symposium issues
    16.00-17.00

    Satellite Symposium

    Fighting multi drug resistance - the right moment, the right drugs

    Satellite Symposium

    Fighting multi drug resistance - the right moment, the right drugs

    Patients with Multi Drug Resistant (MDR) HIV infection and few residual antiretroviral options are very likely to experience progression of the disease and death. To address this important unmet need, new antiretroviral agents are needed with novel mechanisms of action, good safety profile, no drug-drug interactions and no cross-resistance to other HIV drugs. The Symposium will focus on new modes of action currently in development and share latest clinical data conducted so far with ibalizumab, a new humanized IgG4 monoclonal antibody which blocks the entry of HIV by non-competitive binding to CD4. The Italian experience with the use of ibalizumab will also be presented.

    Chairs: C. Mussini, M. Zazzi

    16.00 - 16.05 Speaker's introduction and scientific rationale
    C. Mussini
    16.05 - 16.15 New treatments, new options
    A. Antinori
    16.15 - 16.25 Resistance to Long-Acting Antivirals
    M. Zazzi
    16.25 - 16.45 Building a fully suppressive regimen for patients with MDR - lessons learned
    B. Emu
    16.45 - 16.55 The Italian experience
    A. Castagna
    16.55 - 17.00 Discussion on Symposium issues
    17.00-17.20 Keynote Lectures

    Keynote Lecture

    Chairs: F. Ceccherini - Silberstein, A. De Rossi

    17.00 - 17.20 Genomics and proteomics approaches for studies of HIV eradication
    M. Lichterfeld
    17.30-18.25

    Symposium

    New metabolic challenges in comorbidities

    Symposium

    New metabolic challenges in comorbidities

    HIV ad cART comorbidities are continuously changing their presentations, in parallel with the evolving spectrum of antiretroviral treatment regimens and the demographic and clinical features of people with HIV (PWH). At present, the current scenario of metabolic comorbidities seems to reflect, on one hand, the extended use of potent antiretroviral drugs with a very high safety profile, and, on another hand, the increasing age of PWH and the persisting immune activation. This symposium discusses emerging issues in the field, including prevalence and impact of these complications and explore the potential of old and new tools for their definition and management.

    Chairs: A. Bandera, P. Bonfanti, F. Castelli

    17.30 - 17.40 The growing burden of nonalcoholic fatty liver disease in people aging with HIV
    G. Sebastiani
    17.40 - 17.50 Weight gain and new antiretrovirals: is a real issue?
    S. Cicalini
    17.50 - 18.00 Immune-metabolic interventions as geroprotective agents in HIV
    G. Guaraldi
    18.00 - 18.10 Artificial intelligence in aging: from data collection to data analitics
    C. Grana
    18.10 - 18.25 Discussion on Symposium issues
    18.30-19.30

    Sponsored Symposium

    Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine

    Con il supporto di:

    Sponsored Symposium

    Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine

    Remarkable advances in drug development for the treatment of HIV-1 infection have been achieved in recent years. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development new antiretroviral drugs, the treatment of HIV has and will become much more tolerable and less complicated for people living with HIV (PLWH). Moreover, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy and good tolerability. In this scenario, one of the most recently options considered is 2-drug regimen (2DR) containing highly effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles, with the potential additional advantage to minimize antiretroviral medication burden for improving effectiveness. In this novel therapeutic context, the 2DR consisting of the INSTI dolutegravir (DTG) and the NRTI lamivudine (3TC), represents today the unique regimen extensively studied versus standard 3- or 4-drug regimens both in naïve and virologically suppressed patients. Aim of the symposium is to highlight important considerations for the use of 2DR single tablet DTG/3TC in the context of existing and emerging ARV options.

    Chair: P. Rizzini

    18.30 - 18.45 The robustness of the evidences up to date: challenging the use of 3 drug regimens
    J.M. Gatell
    18.45 - 19.00 How dolutegravir/lamivudine meets the patient needs
    N. Nwokolo
    19.00 - 19.30 Discussion on Symposium issues
    19.30-20.30 ICAR-CROI Awards 2020 for young Italian HIV investigators
  • Room 2
    15.00-16.00

    Expert Meeting

    Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

    Con la sponsorizzazione di:

    Expert Meeting

    Hepatitis C Elimination: the winning challenge of the 8-weeks treatment

    Thanks to the DAAs, the WHO's goal of HCV elimination by 2030 could be achieved more easily. The high efficacy of these antiviral drugs, characterized by great power, few DDIs and short treatment make the patient's journey less onerous and heavy. Clinical trials and RWE data demonstrate not only the high SVR rate of the short therapies but also the improvement of adherence to the treatment. This last aspect is fundamental for the special populations (PWIDs and patients from SERD) because the briefer the therapy, the less burdensome it is for them. The Expert Meeting will focus precisely of the opportunity of the short therapy in the challenge against HCV. In this context, it represents an important step towards the efforts for eliminating the hepatitis C because it evaluates a brief antiviral regimen in untreated patients without cirrhosis and with compensated cirrhosis, across HCV genotypes 1-6. Through a talk show session, the two Professors will explain and convey the main data and results of this HCV turning point to the audience. The latter will be able to intervene in the session thanks to an interactive platform that will allow the physicians to answer the questions formulated by the speakers.

    15.00 - 16.00 Hepatitis C Elimination: the winning challenge of the 8-weeks treatment
    M. Andreoni, M. Puoti
    16.00-17.00

    Oral Communications

    Social Science

    Oral Communications

    Social Science

    Chairs: G. Liuzzi, A. Matteelli, L.A.R. Rancilio

    16.00 - 16.10 OC 1Awareness and perception of accuracy of the U = U message in people living with HIV (PLWHIV), in Italy and correlation with the level of confidence in reference physicians
    A. Cingolani, Roma
    16.10 - 16.20 OC 2Hepatitis C, HIV and Tubercolosis among vulnerable populations in an out-of-hospital setting: a seroprevalence analysis from The week of the poor experience
    G. De Simone, Roma
    16.20 - 16.30 OC 3Engagement of younger generations in the fight against HIV/AIDS
    P. Meli, Bergamo
    16.30 - 16.40 OC 4Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort
    A. Saracino, Bari
    16.40 - 16.50 OC 5BLQ Checkpoint: characteristics of users and services offered. A 5 years review
    G.M. Corbelli, Roma
    16.50 - 17.00 OC 6Sexual behaviour and associated risk for sexual health among men who have sex with men (MSM) in Italy: data from the EMIS 2017 survey
    M. Breveglieri, Bologna
    17.30-18.30

    Oral Communications

    Antiretroviral Therapy

    Oral Communications

    Antiretroviral Therapy

    Chairs: M. Malena, C. Torti

    17.30 - 17.40 OC 7Durability of dolutegravir-based regimens after the first year of therapy
    L. Taramasso, Milano
    17.40 - 17.50 OC 8Switch to RPV+DRV/cobi: 48week results of the PROBE 2 study
    F. Maggiolo, Bergamo
    17.50 - 18.00 OC 9Predictors of virological failure among HIV-1 infected patients switching from an effective first line antiretroviral regimen. A preliminary analysis
    L. Magnasco, Genova
    18.00 - 18.10 OC 10Long term efficacy of dolutegravir + lamivudine as simplification cART in patients with suppressed HIV-RNA
    F. Maggiolo, Bergamo
    18.10 - 18.20 OC 11Lamivudine+dolutegravir (3TC+DTG) switch strategy compared with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed HIV patients: preliminary results from an Italian center
    G. Baldin, Olbia
    18.20 - 18.30 OC 12Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy
    A. Vergori, Roma
    18.30-19.30

    Oral Communications

    HIV Prevention

    Oral Communications

    HIV Prevention

    Chairs: A. Bignardi, T.S. Prestileo, B. Suligoi

    18.30 - 18.40 OC 13Engagement, adherence and rate of discontinuation in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)
    V. Mazzotta, Roma
    18.40 - 18.50 OC 14Pre-Exposure Prophylaxis (PrEP) use at five Infectious Diseases Units in northern Italy (PrEP-Italy study)
    S. Venturelli, Bergamo
    18.50 - 19.00 OC 15Uptake and effects on sexual behaviour in a cohort of PrEP users
    P.L.G. Vinti, Milano
    19.00 - 19.10 OC 16Preventive measures against HIV and sexually transmitted infections among key populations referring to a counseling and testing center in the metropolitan area of Rome
    R. Esvan, Roma
    19.10 - 19.20 OC 17Incidence of STIs and HIV in a cohort of MSM and MtF with high prevalence of risk factors for HIV acquisition evaluated in a PrEP community-based service in Italy: one-year follow-up data from SEX-CHECK study
    D. Testi, Bologna
    19.20 - 19.30 OC 18HIV and motherhood - A survey on women's experiences in the U=U era
    M.G. Di Benedetto, Como
  • Room 3
    17.30-18.30

    Special event

    Meet the Expert

    Meet the Expert

    During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

    Chairs: M. Cascio, S. Mattioli

    17.30 - 18.00 Antiretroviral therapy
    A. Pozniak
    18.00 - 18.30 Transgender
    O. Voza
 
Plenary Room
Room 2
Room 3
14.30 - 14.50

Plenary Room

Keynote Lecture
15.00 - 16.00
16.00 - 17.00

Sponsored Symposium

POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

Symposium

Reaching out: same models for different infections

Oral Communications

Virology

Satellite Symposium

Recent advances in the management of Gram positive infections: the evolving role of long acting therapy
 
17.00 - 17.20

Plenary Room

Keynote Lecture
17.30 - 18.30
18.30 - 19.30

Satellite Symposium

Committed globally to fight HIV and other severe infections

Symposium

Lights and shadows in HIV clinical research

Oral Communications

Comorbidities

Oral Communications

Clinical Hepatitis and Coinfections
Meet the Expert
  • Chemsex
  • Drug-Drug Interactions
 
  • Plenary Room
    14.30-14.50 Keynote Lectures

    Keynote Lecture

    Chairs: S. Di Giambenedetto, F. von Schloesser

    14.30 - 14.50 Orientating in a maze. The Arianna's thread to partner notification
    M.L. Cosmaro
    15.00-16.00

    Sponsored Symposium

    POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

    Con la sponsorizzazione di:

    Sponsored Symposium

    POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations

    The advent of the new antiretroviral drugs has permitted to obtain virological success in the majority of treated patients. This achievement has allowed the clinicians to focus on HRQoL (4th 90) to guarantee a long-term well-being. In this new context, populations defined by clinical conditions are now obsolete:  to achieve the 4th 90 goal we need to consider PLHIV lifestyles by moving from patient profile to personas concept. Each personas is different and has different expectations, therefore is crucial to contemplate all the key factors that contribute to obtain a better quality of life. In this evolving scenario, therapy still has a critical role in controlling the virus, but how can it fulfill doctors' and patients' needs to reach the HRQoL (4th 90)?

    Chairs: A. d'Arminio Monforte, C.F. Perno

    15.00 - 15.30 PLHIV in 2020: interactive discussion on personas
    C. Gervasoni, C. Madeddu, G. Madeddu
    15.30 - 15.45 How therapy can meet patients' needs
    S. Bonora
    15.45 - 16.00 Discussion on Symposium issues
    16.00-16.55

    Symposium

    Reaching out: same models for different infections

    Symposium

    Reaching out: same models for different infections

    The first of the United Nations' 90-90-90 targets to end the HIV epidemic is for 90% of people living with HIV to learn their HIV status. HIV testing is therefore essential to achieving the first 90. The only way to determine a person's HIV status is for them to have an HIV test. What is the best way? HIV testing in healthcare services is the traditional approach. Good results have been accomplished through it but there are some obstacles as  limited access and usability of the healthcare structures and the difficulty of people to undergo the test in the hospital. In recent years, the Point of Care (POC) have been successful to overcome some difficulties and to make easier the access to the test especially for populations who showed reluctance to go to the hospital. The European POC has also created a network to facilitate access to the hospital and to make access to care simpler and faster. It already has the result to accelerate the United Nations' 90-90-90 campaign . Discussing and finding further solutions requires reflection on the experiences that have been carried out by NGOs. Looking for concrete collaborations and new intervention strategies between POC and hospital can bring us closer to the WHO objectives and reinforce the equation Undetectable = Untransmittable (U=U) message. There is an opportunity to improve prevention, testing services and ensure high-quality well-adhered treatment and care for all.

    Chairs: S. Negri, V. Puro, E. Vaccher

    16.00 - 16.10 Amending missed opportunities for HIV testing in healthcare services
    S. Nozza
    16.10 - 16.20 Testing, prevention and treatment outside of the hospital: the checkpoint model
    G.M. Corbelli
    16.20 - 16.30 We are not hard to reach - Bringing people to the hospital and vice versa
    E. Teti
    16.40 - 16.55 Discussion on Symposium issues
    17.00-17.20 Keynote Lectures

    Keynote Lecture

    Chairs: M. Galli, E. Girardi

    17.00 - 17.20 New challenges in virology: SARS-CoV-2
    M.R. Capobianchi
    17.30-18.30

    Satellite Symposium

    Committed globally to fight HIV and other severe infections

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    Committed globally to fight HIV and other severe infections

    Since the introduction of cART there has been increased survival in HIV-infected persons, so nowadays it is important to answer to individual HIV patients needs, going beyond viral suppression, as antiretroviral therapy is a life-long commitment. Furthermore, with the availability of two or three drugs combinations is becoming more crucial the physician's role in choosing and adapting the ART to treat population living with HIV (PLWH) avoiding issues about adherence, potential drug-drug interactions, long-term toxicities given that the PLWH is ageing with increasing comorbidities such as osteoporosis, renal, cardiovascular, metabolic and liver diseases, which need additional drugs. The aim of the symposium is to examine how current antiretroviral agents may be better incorporated into management strategies in daily practice to benefit patient's individuality now and to preserve the future. In this changing scenario, is interesting to show how the well-known NNRTI rilpivirine (RPV) has remained central to several key therapeutic innovations due to its proven durable efficacy & tolerability that delivers multiple benefits for HIV patients. Furthermore, while the global genetic diversity of HIV poses a considerable scientific challenge, the symposium will be an opportunity to discuss on the lnfectivologists & pharma company's commitment to HIV and other infections vaccine research, aiming to address these problems.

    Chair: C. Mussini

    17.30 - 17.45 Indhividuality: beyond viral suppression
    G. Madeddu
    17.45 - 18.00 The rilpivirine perspective: present and future
    S. Lo Caputo
    18.00 - 18.15 Back to basic: paving the way to HIV and other infections vaccines
    A. Castagna
    18.15 - 18.30 Discussion on Symposium issues
    18.30-19.25

    Symposium

    Lights and shadows in HIV clinical research

    Symposium

    Lights and shadows in HIV clinical research

    Evidence based medicine relies on well conducted clinical trials and comprehensive cohort data to draw its indications. However, no experimental design is completely free of drawbacks and limitations. Therefore, the results of different clinical experiences must be read in a critical way understanding which is the right field of application. The problem is further complicated in a constantly expanding field as HIV/AIDS by the need to adequate outcomes and measures to newly defined goals. The symposium will offer a comprehensive discussion about all these critical aspects of clinical management of HIV/AIDS.

    Chairs: P.M. Cinque, N. Gianotti, A. Gori

    18.30 - 18.40 What trials did not show
    F. Maggiolo
    18.40 - 18.50 What we cannot expect from clinical cohorts
    A. Cozzi-Lepri
    18.50 - 19.00 Innovative outcomes: what surrogate outcomes
    M. Santoro
    19.00 - 19.10 Unconventional innovative outcomes
    A. Cingolani
    19.10 - 19.25 Discussion on Symposium issues
  • Room 2
    15.00-16.00

    Oral Communications

    Virology

    Oral Communications

    Virology

    Chairs: S. Menzo, M.C. Re

    15.00 - 15.10 OC 19Defining stable reference genes to analyze cell associated HIV RNA induced by latency reversing agents
    C. Ceriani, Chapel Hill, USA
    15.10 - 15.20 OC 20Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI -experienced patients in Italy: a cross-sectional study
    A. Lazzaro, Torino
    15.20 - 15.30 OC 21HIV-DNA from rectal GALT is a valid marker to characterize the viral reservoir
    C. Stingone, Roma
    15.30 - 15.40 OC 22Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
    Y. Bouba, Roma
    15.40 - 15.50 OC 23Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study
    A. Emiliozzi, Siena
    15.50 - 16.00 OC 24Prevalence of high-risk HPV genotypes and HPV genotypes targeted by the nine-valent vaccine Gardasil-9 and the associated risk factors
    E. Bruzzesi, Modena
    16.00-17.00

    Satellite Symposium

    Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

    Con la sponsorizzazione non condizionante di:

    Satellite Symposium

    Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

    Gram positive infections are a continuing challenge for clinicians: while classic pathogens still persist and evolve acquiring new mechanisms of resistance, new pathogens emerge with intrinsic multiple antibiotics resistance profiles, causing life-threatening infections as nosocomial pneumonia and intravascular device associated bloodstream infections. Not less important, the population at risk, i.e. elderly with multiple comorbidities or recipients of various foreign bodies, is increasing. New therapy options are required, with increased bactericidal activity and antibacterial spectrum that includes multiple resistant pathogens. Recently, the antimicrobial armamentarium has been enriched by a lipoglycopeptide with a very prolonged half-life (dalbavancin) enabling treatment with a single intravenous administration.  Pharmacokinetic profile and convenient single dosing make dalbavancin an interesting option for other serious Gram positive infections requiring prolonged treatment courses, for example bone infections, endocarditis and intravascular line associated infections. The aim of this workshop is to focus on new pharmacological, clinical and pharmacoeconomical data with dalbavancin in order to provide an up-to-date of the actual and potential future role of this options for serious Gram positive infections.

    Chair: M. Tavio

    16.00 - 16.15 Gram+ subacute infections
    P. Viale
    16.15 - 16.30 The evolving role of long acting therapy in the management of Gram positive infections
    M. Andreoni
    16.30 - 16.45 Dalbavancin: pharmacokinetical data
    P. Viale
    16.45 - 17.00 Dalbavancin: pharmacoeconomical data
    M. Andreoni
    17.30-18.30

    Oral Communications

    Comorbidities

    Oral Communications

    Comorbidities

    Chairs: D. Francisci, G. Parruti

    17.30 - 17.40 OC 25Fat distribution and density in PLWH with >=5% weight gain
    M. Menozzi, Modena
    17.40 - 17.50 OC 26Statin Eligibility in People living with HIV: are we using the right tools to identify patients at risk of developing major cardiovascular disease?
    M. Mazzitelli, Catanzaro
    17.50 - 18.00 OC 27Prevalence, predictors and evolution of lean non-alcoholic fatty liver disease in HIV mono-infected patients
    A. Cervo, Palermo
    18.00 - 18.10 OC 28NAFLD with significant fibrosis in PLWH informs the natural history of cardiovascular disease
    J. Milic, Modena
    18.10 - 18.20 OC 29Decline of metabolic syndrome and increase in overweight in HIV infected patients from 2005-2015
    L. Taramasso, Milano
    18.20 - 18.30 OC 30Progression of anal/cervical dysplasia is associated with Human Papillomavirus (HPV) and Syphilis coinfection in HIV-infected patients
    C. Tincati, Milano
    18.30-19.30

    Oral Communications

    Clinical Hepatitis and Coinfections

    Oral Communications

    Clinical Hepatitis and Coinfections

    Chairs: G. Mazzola, T.A. Santantonio

    18.30 - 18.40 OC 31The contribution of late presentation and late ART initiation to TB-HIV occurrence across four countries
    E. Girardi, Roma
    18.40 - 18.50 OC 32HPV 16 and 18 infections contribute to development of anal cytological abnormalities in a cohort of PLWH
    N. Squillace, Monza
    18.50 - 19.00 OC 33Impact of syphilis on the risk of HIV viral rebound in HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort
    A. Giacomelli, Milano
    19.00 - 19.10 OC 34Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study
    A. d'Arminio Monforte, Milano
    19.10 - 19.20 OC 35Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees
    M. Macera, Napoli
    19.20 - 19.30 OC 36HCV treatment and reinfection risk in injecting drug users in Residential Treatment Setting for drug addiction. San Patrignano HCV-free
    A. Boschini, Rimini
  • Room 3
    17.30-18.30

    Special event

    Meet the Expert

    Meet the Expert

    During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

    Chairs: M. Breveglieri, S. Mattioli

    17.30 - 18.00 Chemsex
    C. Di Feliciantonio
    18.00 - 18.30 Drug-Drug Interactions
    D. Cattaneo
 
Plenary Room
Room 2
Room 3
14.30 - 15.15

Plenary Room

Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient management
15.20 - 16.20
16.20 - 17.20
17.20 - 18.20
18.20 - 19.20

Satellite Symposium

HIV: understanding the real burdens of the disease

Symposium

Immune control over HIV reservoir

Symposium

Challenges in PrEP implementation and TasP confidence

Symposium

HIV and Coinfections: new challenges for 2020

Oral Communications

Basic Science and Immunology

Expert Meeting

Enhancing care for people living with HIV: current and future of monitoring approaches

Oral Communications

Clinical HIV

Expert Meeting

Urgent global challenges in infectious diseases: fight together against HIV and AMR
 
Meet the Expert
  • Immunological update
  • Cure
 
  • Plenary Room
    14.30-15.15 Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient management

    Round Table

    HIV in COVID-19 era: how to ensure quality of care and outpatient management

    2020 has been so far very challenging for infectious disease specialists around the world especially for new coronavirus. The aim of the round table is to discuss how this emergency impacted on the outpatient management of HIV infected patients and, more generally, on their quality of care. Clinicians will talk about clinic experiences, recommendations and organizational models on management and security, diagnosis, screening, telemedicine while patients will relate about their perception on the quality of care with a focus on PrEP and STI management.

    Chairs: M. Andreoni, A.M. Cattelan

    Participants: M.G. Di Benedetto, M. Lichtner, S. Mattioli, S. Rusconi
    15.20-16.20

    Satellite Symposium

    HIV: understanding the real burdens of the disease

    Con il supporto incondizionato di:

    Satellite Symposium

    HIV: understanding the real burdens of the disease

    The today new standards of highly virologically effective antiretroviral regimens fully authorize clinicians to move the attention from pursuing viro-immunological outcomes, namely efficacy, to also considering in the clinical practice concrete strategies for preserving both quality of life and long-term well-being, namely effectiveness. Reducing all kind of medication burdens, both pharmacological and taking medicine ones, suggest a patient-centered approach.

    Chair: C. Mussini

    15.20 - 15.35 Reducing ARV and taking medicines burdens for improving effectiveness
    M. Andreoni
    15.35 - 15.50 The evaluation of patient complexity in the setting of ARV deprescribing
    G. Guaraldi
    15.50 - 16.15 Discussion on Symposium issues
    16.15 - 16.20 Closing remarks
    C. Mussini
    16.20-17.15

    Symposium

    Immune control over HIV reservoir

    Symposium

    Immune control over HIV reservoir

    Despite full control over HIV replication by cART, HIV has been shown to persist in lymphoid tissues, and represent a major obstacle to HIV eradication. The symposium will review the major immunologic pathways behind immune control over HIV, alongside the distinguishing features of patients with progressive versus non-progressive disease.

    Chairs: A. Caruso, M.S. Clerici, L. Sarmati

    16.20 - 16.30 Models of natural protection against HIV infection and progression
    M. Biasin
    16.30 - 16.40 Innate immunity: don't forget the macrophages!
    G. Poli
    16.40 - 16.50 Inflammatory stem cells
    A. De Maria
    16.50 - 17.00 Killing HIV by bNABs: apocalypse, now?
    L. Lopalco
    17.00 - 17.15 Discussion on Symposium issues
    17.20-18.15

    Symposium

    Challenges in PrEP implementation and TasP confidence

    Symposium

    Challenges in PrEP implementation and TasP confidence

    Pre-exposure prophylaxis (PreP) for HIV has proven effective in reducing the number of new infections in several trials and in different settings, while treatment as prevention (TasP) is one of the major advancements in the HIV field, becoming a major argument for supporting both the universal treatment and test and treatment strategies. However, issues are arising in PreP implementation in clinical practice, while the trust in TasP may be challenging when it comes to the real world, as both patients and clinicians may have different interpretations, expectations and confidence.

    Chairs: S. Maugeri, D. Ripamonti, L. Sighinolfi

    17.20 - 17.30 PrEParing providers
    S. Venturelli
    17.30 - 17.40 Challenges in becoming a PrEP user
    A. Infante
    17.40 - 17.50 How much trust in TasP?
    S. Venturelli
    17.50 - 18.00 Consequences of TasP
    A. Infante
    18.00 - 18.15 Discussion on Symposium issues
    18.20-19.25

    Symposium

    HIV and Coinfections: new challenges for 2020

    Symposium

    HIV and Coinfections: new challenges for 2020

    In the last years the control of HIV replication  obtained excellent results with more than 90% of patients being undetectable. However, clinical challenges in the management of HIV infected patients still remain, such as the presence of co-infections with viruses such as HBV and HPV, both involved in cancer development, as well as with tuberculosis. The symposium will focus on such pathogens, discussing the challenges in terms of clinical history, diagnosis and treatment.

    Chairs: R. Bruno, G. Taliani

    18.20 - 18.30 Critical epidemiological and virological insights on HBV coinfection
    V. Svicher
    18.30 - 18.40 HBV: from new drugs to functional cure
    M. Puoti
    18.40 - 18.50 HPV-associated ano-genital lesions in HIV patients
    M. Giuliani
    18.50 - 19.00 HPV-driven oropharyngeal cancer in the HIV/AIDS patient
    P. Boscolo Rizzo
    19.00 - 19.10 Which is the best approach to screen HIV-infected individuals for latent tuberculosis infection in Italy?
    D. Goletti
    19.10 - 19.25 Discussion on Symposium issues
  • Room 2
    15.20-16.20

    Oral Communications

    Basic Science and Immunology

    Oral Communications

    Basic Science and Immunology

    Chairs: C. Agrati, C.M. Mastroianni

    15.20 - 15.30 OC 37Reduced probability of achieving optimal viro-immunological condition in subjects with vertical transmission of HIV reaching adult age with unsuppressed HIV RNA or incomplete immunological recovery
    A. Celotti, Brescia
    15.30 - 15.40 OC 38Immunological recovery in T-cell activation after DAA treatment and SVR in HIV positive subjects with chronic hepatitis C
    F. Maggiolo, Bergamo
    15.40 - 15.50 OC 39Higher frequency of CD4+PD1+ T cells and Interferon-Stimulate Genes are associated to a decrease in CD4+ Treg levels in HIV-1 infected patients
    F. Frasca, Roma
    15.50 - 16.00 OC 40Macrophage transcriptome profiling upon CCL2 neutralization identifies an association between activation of antiviral responses and HIV-1 restriction
    L. Fantuzzi, Roma
    16.00 - 16.10 OC 41High frequency of Myeloid Derived Suppressor Cells in Immunological Non Responders: possible involvement in CD4 T cell recovery
    A. Sacchi, Roma
    16.10 - 16.20 OC 42HIV-binding specificity and -neutralizing potency after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study).
    G. Siracusano, Milano
    16.20-17.20

    Expert Meeting

    Enhancing care for people living with HIV: current and future of monitoring approaches

    Con la sponsorizzazione non condizionante di:

    Expert Meeting

    Enhancing care for people living with HIV: current and future of monitoring approaches

    The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiretroviral (ART) drugs, which can suppress HIV-1 replication to undetectable levels. Despite this HIV cannot currently be eradicated from the body, and antiretroviral treatment thus has to be indefinitely maintained. People living with HIV will have to go a long way and only CD4+ lymphocytes count and HIV-RNA load will not be able to adequately inform the doctor and the researcher about the real benefit of the ART. New approaches need to be defined for monitoring people with HIV infection, including clinical, virological, immunological parameters and also the point of view of people living with HIV. The purpose of this Expert Meeting is to highlight the evidence on different biomarkers or innovative approach use in research and clinical settings, to better define the management of HIV infection.

    Chairs: A. Di Biagio, F. Maggiolo

    16.20 - 16.25 Introduction
    F. Maggiolo
    16.25 - 16.35 Virology
    S. Rusconi
    Gruppo di lavoro: N. Gianotti, R. Maserati, S. Rusconi, M. Zazzi
    16.35 - 16.45 Immunology and inflammation
    G.C. Marchetti
    Gruppo di lavoro: A. Bandera, A. Calcagno, M. Lichtner, G. Marchetti
    16.45 - 16.55 Comorbidities
    G. Madeddu
    Gruppo di lavoro: S. Bonora, G. Madeddu, M. Borderi, P. Maggi
    16.55 - 17.05 PROs, Patient-reported outcomes
    A. Cingolani
    Gruppo di lavoro: A.M. Cattelan, A. Cingolani, S. Lo Caputo, S. Nozza
    17.05 - 17.15 Discussion
    17.15 - 17.20 Closing remarks
    A. Di Biagio
    17.20-18.20

    Oral Communications

    Clinical HIV

    Oral Communications

    Clinical HIV

    Chairs: A. Calcagno, M.C. Moioli

    17.20 - 17.30 OC 43Machine learning statistical approach to identify HIV co-infected patients with asymptomatic neurosyphilis
    L. Celani, Roma
    17.30 - 17.40 OC 44Body composition changes in HIV: do INSTI matter?
    J. Milic, Modena
    17.40 - 17.50 OC 45Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA
    S. Cicalini, Roma
    17.50 - 18.00 OC 46Impact of antiretroviral therapy on gut CD4 T cells activation: differences between naïve and long-term treated HIV-1 infected patients
    G.P. Innocenti, Roma
    18.00 - 18.10 OC 47Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy
    S. Cannizzo, Milano
    18.10 - 18.20 OC 48Evaluation of the impact of resistance on virological efficacy of STR regimens and emergence of resistance at virological failure
    G. Stella, Arezzo
    18.20-19.20

    Expert Meeting

    Urgent global challenges in infectious diseases: fight together against HIV and AMR

    Con la sponsorizzazione non condizionante di:

    Expert Meeting

    Urgent global challenges in infectious diseases: fight together against HIV and AMR

    The objective of this expert meeting is to give an update on the current global health challenges in infectious diseases, giving a clear picture on how HIV and AMR are impacting our country and patients' life. Prevention and protection of future generations is becoming increasingly important in HIV: awareness, innovative drugs and quality of life are essential to ensure the achievement of Global UNAIDS objectives. Together with HIV, the fight against drug resistance is a priority at worldwide level with Antimicrobial resistance (AMR) as the most important infectious disease threat of our time. The impact of AMR on patients' life creates the need to accelerate the fight in hospital setting and to ensure the dissemination of strategies and tools for an appropriate management.

    Chair: G. Di Perri

    18.20 - 18.30 Introduction
    18.30 - 18.50 Objective: Future HIV free generations
    A. Antinori
    18.50 - 19.10 AMR: impact on patients' life and strategies for an appropriate management
    P. Viale
    19.10 - 19.20 Discussion on Expert Meeting issues
  • Room 3
    17.20-18.20

    Special event

    Meet the Expert

    Meet the Expert

    During these Sessions, participants will have the opportunity to informally discuss with top ICAR Experts and exchange with them personal views, receive practical insights about specific topics. Guided by Facilitators, these sessions represent an important opportunity for all delegates to sit down and converse on a more one-to-one level.

    Chairs: D. Calzavara, S. Mattioli

    17.20 - 17.50 Immunological update
    G. Silvestri
    17.50 - 18.20 Cure
    F.R. Simonetti
 
Plenary Room
Room 2
14.30 - 15.15

Symposium

The Fast-Track Cities initiative and the Italian state of the art
15.20 - 15.50
15.50 - 16.20
16.20 - 17.20
17.20 - 18.20
Special Session on HIV and COVID in Italy

Symposium

ART treatment: when the patient's journey becomes difficult

Symposium

Proud to be women, proud to fight HIV

Oral Communications

Immunopathogenesis

Oral Communications

Hepatitis and Clinical Virology

Oral Communications

Social Science and Epidemiology

Oral Communications

Pharmacology
18.20 - 18.35

Plenary Room

ICAR 2020 Special Awards
18.35 - 18.45

Plenary Room

ICAR 2020 Closing remarks
 
  • Plenary Room
    14.30-15.15

    Symposium

    The Fast-Track Cities initiative and the Italian state of the art

    Con la sponsorizzazione non condizionante di:

    Symposium

    The Fast-Track Cities initiative and the Italian state of the art

    The Fast-Track Cities initiative is a global partnership between cities and municipalities around the world and four core partners - the International Association of Providers of AIDS Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat), and the City of Paris. Launched on World AIDS Day 2014, the network has grown to include more than 300 cities and municipalities that are committed to attain the UNAIDS 90-90-90 targets by 2020. The aim of the symposium is to discuss the global initiatives and to focus on the Italian Fast-Track Cities state of the art, in a round table involving the different Italian Fast-Track Cities' stakeholders.

    Chair: B. Audoin

    Discussants: A. d'Arminio Monforte, M.R. Iardino

    14.30 - 14.35 Introduction
    B. Audoin
    14.35 - 14.40 The Global Network
    R.B. Leite
    14.45 - 15.15 Round Table "The Italian Fast-Track Cities"
    Participants: A. Cascio, G. Cenderello, A. Di Biagio, M. Di Pietro, F. Vichi, F. Maggiolo, D. Maineri
    15.20-16.20

    Special event

    Special Session on HIV and COVID in Italy

    Special event

    Special Session on HIV and COVID in Italy

    Chairs: G. Angarano, E. Vicenzi

    15.20 - 15.30 OC 49SARS-CoV-2 infection in PLWHIV: a large single center cohort
    F. Maggiolo, Bergamo
    15.30 - 15.40 OC 50Newly diagnosed HIV infections at a Counseling and Testing Service during COVID-19 pandemic
    F. Gili, Roma
    15.40 - 15.50 OC 51HIV and SARS-CoV-2 co-infection: epidemiological, clinical and immunological aspects among HIV-positive young individuals
    C. Vanetti, Milano
    15.50 - 16.00 OC 52Clinical features and outcomes of HIV patients with coronavirus disease 2019
    C. Gervasoni, Milano
    16.00 - 16.10 OC 53Antibody responses to SARS -CoV-2 in people living with HIV (PLWH) in Umbria
    C. Papalini, Perugia
    16.20-17.15

    Symposium

    ART treatment: when the patient's journey becomes difficult

    Symposium

    ART treatment: when the patient's journey becomes difficult

    The high efficacy and tolerability of antiretroviral drugs nowadays available might give the impression that treating HIV infection is today an easy task. That could even be true in a fairly large proportion of patients but, as in every population, ties exist and these extremes of the Gaussian curve are the challenging patients. The symposium will offer a comprehensive overlook on different difficult to treat patients offering hints to an optimized clinical management in these specific situations. When the play gets tough, tough guys start to play.

    Chairs: T. Bini, L. Calza, M. Cernuschi

    16.20 - 16.30 Advanced naives
    A. Antinori
    16.30 - 16.40 Multi-drug resistant
    A. Castagna
    16.40 - 16.50 Fragile-social desparities
    A. Saracino
    16.50 - 17.00 Addressing personal barriers
    M. Oldrini
    17.00 - 17.15 Discussion on Symposium issues
    17.20-18.15

    Symposium

    Proud to be women, proud to fight HIV

    Symposium

    Proud to be women, proud to fight HIV

    The efforts made so far in terms of controlling the HIV epidemic on a global level have left women behind compared to the achievement of the objectives set by the WHO. This is because a tailored approach specifically aimed at the female population is far from being applied both in terms of implementation of prevention tools and of clinical and psychological management of women. The objective of this symposium is to focus attention and reflect on peculiar aspects of women's health to ensure that this gap is quickly bridged.

    Chairs: G. Lapadula, A. Moznich, G. Scarlatti

    17.40 - 17.50 Women well-being and safe childbearing: updated management strategies
    F. Sabbatini
    17.50 - 18.00 Women are from Venus - Implications for prevention and cure
    G.C. Marchetti
    18.00 - 18.15 Discussion on Symposium issues
    16.45-17.00 ICAR 2020 Special Awards

    ICAR 2020 Special Awards

    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio

      Premiazioni
    18.35-18.45

    Symposium

    Closing remarks

    Closing remarks

    Chairs: M. Clementi, S. Mattioli, C. Mussini, G. Silvestri, M. Tavio

      Closing 12th ICAR
  • Room 2
    15.20-15.50

    Oral Communications

    Immunopathogenesis

    Oral Communications

    Immunopathogenesis

    Chairs: M. Nasi, G. Nunnari

    15.20 - 15.30 OC 54Psycosexual health and systemic, mucosal immune activation and in hiv-infected ART suppressed and uninfected women: evaluation of biomarkers and environmental stimuli
    P. Nijhawan, Roma
    15.30 - 15.40 OC 55Inflammatory burden in people living with four-class drug resistant HIV: data from the PRESTIGIO registry
    T. Clemente, Milano
    15.40 - 15.50 OC 56Gut microbial dysbiosis is linked to immune-reconstitution and CD4+ T-cell skewing in MSM with high Framingham Risk Score
    G. Ancona, Milano
    15.50-16.20

    Oral Communications

    Hepatitis and Clinical Virology

    Oral Communications

    Hepatitis and Clinical Virology

    Chairs: N. Coppola, G. Verucchi

    15.50 - 16.00 OC 57Unexpected rising in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
    L. Piermatteo, Roma
    16.00 - 16.10 OC 58HCV genetic variability in patients with related hepatocellular carcinoma
    A. Di Fraia, Napoli
    16.10 - 16.20 OC 59Prevalence and Resistance Analysis of Unusual Hepatitis C Virus (HCV) Subtypes within the Italian Resistance Network VIRONET-C
    V.C. Di Maio, Roma
    16.20-17.20

    Oral Communications

    Social Science and Epidemiology

    Oral Communications

    Social Science and Epidemiology

    Chairs: A. Franco, M. Manfredini, G. Orofino

    16.20 - 16.30 OC 60 A less recent diagnosis is associated with local transmission clusters among HIV-1 primary infections in Rome
    L. Fabeni, Roma
    16.30 - 16.40 OC 61High HIV Prevalence following Screening of Subjects with HIV Indicator Conditions in a Hospital Setting
    C. Tincati, Milano
    16.40 - 16.50 OC 62The cascade of care as tool to promote a more effective city-wide program against HIV/AIDS
    F. Maggiolo, Bergamo
    16.50 - 17.00 OC 63Causes and incidence of hospitalization in patients enrolled in the ICONA cohort
    S. Nozza, Milano
    17.00 - 17.10 OC 64The 4th Ninety in the 4th Decade
    A. Bove, Roma
    17.10 - 17.20 OC 65General Practitioners and PLWH: what do patients think?
    S.R. Bruno, Foggia
    17.20-18.20

    Oral Communications

    Pharmacology

    Oral Communications

    Pharmacology

    Chairs: S. Bonora, C. Gervasoni

    17.20 - 17.30 The importance of deprescribing in HIV
    J. Moltò
    17.30 - 17.40 OC 66Use of direct oral anticoagulants in people living with HIV: a single-center experience
    C. Gervasoni, Milano
    17.40 - 17.50 OC 67Pharmacokinetics of once-daily doravirine over 72 hours following drug cessation
    M. Mazzitelli, Catanzaro
    17.50 - 18.00 OC 68Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure
    M. Ferrara, Torino
    18.00 - 18.10 OC 69Bictegravir plasma and intracellular pharmacokinetics in in the clinical setting
    M. Ferrara, Torino
    18.10 - 18.20 OC 70Generic pre-exposure prophylaxis formulations: a comparison of tenofovir trough concentrations
    D. Cattaneo, Milano

Plenary session

Special events session

Pre-Conference courses session

Symposium session

Oral Communications session

Oral Poster session

Sponsored session

×
Chiudi